KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Other Working Capital Changes (2016 - 2025)

NovoCure (NVCR) has disclosed Other Working Capital Changes for 12 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 115.05% to -$2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 17.08% year-over-year, with the annual reading at -$5.3 million for FY2025, 17.08% up from the prior year.
  • Other Working Capital Changes hit -$2.6 million in Q4 2025 for NovoCure, down from -$2.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $920000.0 in Q2 2025 to a low of -$4.4 million in Q1 2021.
  • Historically, Other Working Capital Changes has averaged -$2.0 million across 5 years, with a median of -$1.9 million in 2021.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 1852.89% in 2021 and later soared 150.3% in 2025.
  • Year by year, Other Working Capital Changes stood at -$2.2 million in 2021, then increased by 24.89% to -$1.7 million in 2022, then decreased by 10.67% to -$1.8 million in 2023, then skyrocketed by 33.46% to -$1.2 million in 2024, then plummeted by 115.05% to -$2.6 million in 2025.
  • Business Quant data shows Other Working Capital Changes for NVCR at -$2.6 million in Q4 2025, -$2.4 million in Q3 2025, and $920000.0 in Q2 2025.